Clinical Trial Update: Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial of alefacept for steroid-refractory chronic graft-versus-host disease was terminated, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Alefacept (Alefacept)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Graft-versus-host Disease | Phase 2 | Status: TERMINATED | Results posted: 2013-08-13